(Q46830791)

25 December 2017

title

Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients (English)

1 reference

25 December 2017

main subject

Cold agglutinin disease

1 reference

1 reference

1

Claudia Schöllkopf

0 references

author name string

Claudia Schöllkopf

1

1 reference

25 December 2017

Lars Kjeldsen

2

1 reference

25 December 2017

Ole Weiss Bjerrum

3

1 reference

25 December 2017

Hans Torben Mourits-Andersen

4

1 reference

25 December 2017

Johan Lanng Nielsen

5

1 reference

25 December 2017

Bjarne Egelund Christensen

6

1 reference

25 December 2017

Bjarne Anker Jensen

7

1 reference

25 December 2017

Bjarne Bach Pedersen

8

1 reference

25 December 2017

Ellen Birkerod Taaning

9

1 reference

25 December 2017

Tobias Wirenfeldt Klausen

10

1 reference

25 December 2017

Henrik Birgens

11

1 reference

25 December 2017

publication date

1 February 2006

1 reference

25 December 2017

published in

Leukemia & Lymphoma

1 reference

25 December 2017

volume

47

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

253-260

1 reference

25 December 2017

Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

New treatment approaches to indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

Acute phase haemolysis in chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500286481

10.1080/10428190500286481

21 January 2018

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017